Sunshine Biopharma Ownership
| SBFM Stock | USD 2.28 0.05 2.24% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Sunshine |
Sunshine Stock Ownership Analysis
The company has price-to-book ratio of 0.25. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sunshine Biopharma recorded a loss per share of 127.9. The entity last dividend was issued on the 6th of April 2020. The firm had 1:20 split on the 8th of August 2024. Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada. Sunshine Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Sunshine Biopharma contact Steve Slilaty at 954-515-0810 or learn more at https://sunshinebiopharma.com.Besides selling stocks to institutional investors, Sunshine Biopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sunshine Biopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sunshine Biopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sunshine Biopharma Quarterly Liabilities And Stockholders Equity |
|
Sunshine Biopharma Insider Trades History
About 7.0% of Sunshine Biopharma are currently held by insiders. Unlike Sunshine Biopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sunshine Biopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sunshine Biopharma's insider trades
Sunshine Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sunshine Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sunshine Biopharma backward and forwards among themselves. Sunshine Biopharma's institutional investor refers to the entity that pools money to purchase Sunshine Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Main Street Group Ltd | 2024-09-30 | 0.0 | Nordwand Advisors Llc | 2024-12-31 | 0.0 | Connective Capital Management Llc | 2024-12-31 | 11.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.6 K | Ubs Group Ag | 2024-12-31 | 868 | Sbi Securities Co Ltd | 2024-12-31 | 709 | Bank Of America Corp | 2024-12-31 | 5.0 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 4.0 | Td Waterhouse Canada Inc | 2024-12-31 | 1.0 | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 1.0 | Rise Advisors, Llc | 2024-12-31 | 1.0 |
Sunshine Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sunshine Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sunshine Biopharma Outstanding Bonds
Sunshine Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sunshine Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sunshine bonds can be classified according to their maturity, which is the date when Sunshine Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Sunshine Biopharma Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 21st of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 15th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of January 2025 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.